UMB Bank N A MO cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.7% during the third quarter, Holdings Channel reports. The fund owned 16,562 shares of the biopharmaceutical company’s stock after selling 112 shares during the period. UMB Bank N A MO’s holdings in Celgene Corporation were worth $1,732,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. World Asset Management Inc boosted its stake in shares of Celgene Corporation by 2.0% in the third quarter. World Asset Management Inc now owns 76,818 shares of the biopharmaceutical company’s stock worth $8,030,000 after buying an additional 1,515 shares during the last quarter. Loeb Partners Corp boosted its stake in shares of Celgene Corporation by 12.0% in the third quarter. Loeb Partners Corp now owns 7,000 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 750 shares during the last quarter. Stanley Laman Group Ltd. boosted its stake in shares of Celgene Corporation by 13.7% in the third quarter. Stanley Laman Group Ltd. now owns 10,356 shares of the biopharmaceutical company’s stock worth $1,083,000 after buying an additional 1,248 shares during the last quarter. DnB Asset Management AS boosted its stake in shares of Celgene Corporation by 5.6% in the third quarter. DnB Asset Management AS now owns 69,278 shares of the biopharmaceutical company’s stock worth $7,242,000 after buying an additional 3,700 shares during the last quarter. Finally, Horan Capital Advisors LLC. boosted its stake in shares of Celgene Corporation by 1.8% in the third quarter. Horan Capital Advisors LLC. now owns 26,058 shares of the biopharmaceutical company’s stock worth $2,724,000 after buying an additional 465 shares during the last quarter. 76.32% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ:CELG) traded up 0.34% on Friday, reaching $117.48. The company’s stock had a trading volume of 3,537,705 shares. The firm’s 50-day moving average price is $117.82 and its 200 day moving average price is $109.36. The company has a market cap of $91.07 billion, a P/E ratio of 44.62 and a beta of 1.74. Celgene Corporation has a 52-week low of $93.05 and a 52-week high of $127.00.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.10. Celgene Corporation had a return on equity of 70.48% and a net margin of 19.71%. The business had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same period in the prior year, the business earned $1.23 EPS. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. Equities analysts anticipate that Celgene Corporation will post $5.92 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright laws. The correct version of this article can be read at http://www.dailypolitical.com/2017/01/13/umb-bank-n-a-mo-sells-112-shares-of-celgene-corporation-celg.html.

A number of brokerages have recently commented on CELG. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $129.09 price target for the company. in a report on Wednesday, December 14th. Oppenheimer Holdings, Inc. began coverage on Celgene Corporation in a report on Tuesday, November 29th. They set an “outperform” rating and a $141.00 price target for the company. Piper Jaffray Companies reiterated a “buy” rating on shares of Celgene Corporation in a report on Tuesday, October 18th. BMO Capital Markets reiterated an “outperform” rating and set a $142.00 price target on shares of Celgene Corporation in a report on Tuesday, December 6th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $145.00 price target on shares of Celgene Corporation in a report on Tuesday, December 20th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, twenty-six have assigned a buy rating and one has issued a strong buy rating to the company. Celgene Corporation has a consensus rating of “Buy” and a consensus price target of $137.30.

In related news, Director Michael A. Friedman sold 18,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $116.10, for a total transaction of $2,159,460.00. Following the transaction, the director now directly owns 18,600 shares of the company’s stock, valued at approximately $2,159,460. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Corp /De/ Celgene purchased 800,150 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. Corporate insiders own 0.97% of the company’s stock.

About Celgene Corporation

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.